10-Q: Myriad Genetics Reports Q1 2025 Results: Revenue Declines Amid Leadership Changes

Myriad Genetics' Q1 2025 revenue decreased to $195.9 million, impacted by changes in pharmacogenomics coverage and leadership transitions.

Summary

• Myriad Genetics reported a net loss of $0.1 million for the first quarter of 2025, compared to a net loss of $26.0 million for the same period in 2024.
• Revenue for Q1 2025 was $195.9 million, a decrease from $202.2 million in Q1 2024.
• The decrease in revenue was primarily driven by a decline in pharmacogenomics revenue due to changes in coverage by UnitedHealthcare.
• Hereditary Cancer revenue also decreased slightly, while Prenatal revenue increased.
• The company's cash and cash equivalents decreased to $91.8 million as of March 31, 2025.
• Samraat Raha has been appointed President and Chief Executive Officer, effective April 30, 2025.
• Mark Verratti has been appointed Chief Operating Officer, effective April 30, 2025.
• Brian Donnelly has been appointed Chief Commercial Officer, effective May 1, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the net loss improved, revenue declined, and the company faces challenges with reimbursement coverage. Leadership changes add uncertainty.

Positives

• Net loss significantly improved from $26.0 million in Q1 2024 to $0.1 million in Q1 2025.
• Prenatal revenue increased by $5.0 million due to an 11% increase in average revenue per test.
• The company expects to receive a tax refund of approximately $13 million during 2025 related to the CARES Act.
• Cost of revenue decreased by $2.9 million compared to the same period in the prior year.
• The company remains committed to disciplined cost management while maintaining investments in key strategic areas, such as research and development.

Negatives

• Q1 2025 revenue decreased to $195.9 million from $202.2 million in Q1 2024.
• Pharmacogenomics revenue decreased by $7.9 million due to changes in UnitedHealthcare coverage.
• Hereditary Cancer revenue decreased by $1.8 million due to a 5% decrease in average revenue per test.
• Tumor Profiling revenue decreased by $1.6 million due primarily to a decrease in testing volume for EndoPredict due to the sale of our EndoPredict business in August 2024.
• Cash and cash equivalents decreased to $91.8 million as of March 31, 2025.

Risks

• Changes in governmental or private insurers coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests, including with respect to UnitedHealthcare's coverage decisions to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including our GeneSight test.
• Increased competition and the development of new competing tests.
• The risk that we may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all.
• The risk that we may not successfully develop new markets or channels for our tests.
• The risk that we are not able to secure additional financing to fund our business, if needed, in a timely manner or on favorable terms, if it all.
• The risk that we may be unable to comply with financial or operating covenants under our credit or lending agreements.
• The risk that we may not be able to maintain effective disclosure controls and procedures and internal control over financial reporting.
• Risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and risks related to the amount of our insurance coverage limits and scope of insurance coverage with respect thereto.

Future Outlook

The company expects the UnitedHealthcare coverage decision to continue to negatively affect revenue in future periods. The company intends to continue to develop and enhance our products and services to support growth, improve patient and provider experience, and reach more patients of all backgrounds.

Industry Context

The molecular diagnostics and precision medicine industry is experiencing convergence of personalized molecular data and digital and virtual consumer trends, transforming traditional models of care. Myriad Genetics is focusing on innovation and growth in Oncology, Women's Health, and Pharmacogenomics to address healthcare needs through innovative solutions and services.

Comparison to Industry Standards

• It is difficult to compare Myriad's results directly to industry standards without specific competitor data.
• However, the decrease in pharmacogenomics revenue due to coverage changes highlights the vulnerability of diagnostic companies to payer decisions, a common industry challenge.
• Companies like Exact Sciences and Guardant Health, which focus on cancer diagnostics, may serve as benchmarks for growth and market penetration in the oncology space.
• Myriad's focus on women's health also positions it against companies like Natera, which specializes in prenatal testing.

Management Changes

Legal Proceedings

• In June 2023, the Company received a civil investigative demand pursuant to the False Claims Act from the United States Department of Justice concerning whether the Company offered or paid remuneration to physicians at Carolina Urology Partners, PLLC, in exchange for referrals.
• On January 22, 2025, the U.S. District Court for the Western District of North Carolina unsealed a qui tam complaint, filed on November 3, 2022, against Carolina Urology Partners, PLLC, and certain of its current or former physician partners, and the Company and certain of its former employees, alleging violations of the False Claims Act.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and the impact of reimbursement changes.
• Employees may be affected by the leadership changes and the company's cost management efforts.
• Customers (healthcare providers and patients) may experience changes in access to and coverage of Myriad's tests.

Next Steps

• The company plans to accelerate electronic medical records (EMR) integrations.
• The company plans to expand sales channels, including into large health systems.
• The company plans to cross sell our portfolio of testing products to providers.
• The company plans to enhance our testing products within medical guidelines.
• The company plans to demonstrate our clinical differentiation and value compared to the standard of care.
• The company plans to optimize our revenue cycle processes.
• The company also continue to invest in clinical evidence development to support the growth of our existing products and launch of new products, such as FirstGene, Precise Liquid, and Precise molecular residual disease (MRD) which we expect will help us continue to grow.

Key Dates

Keywords

revenue, Myriad Genetics, pharmacogenomics, genetics, testing, oncology, prenatal, financial results, Q1 2025